Literature DB >> 25091051

BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells.

Xuexia Zhou1, Xuebing Li2, Yuanming Cheng1, Wenwu Wu1, Zhiqin Xie1, Qiulei Xi3, Jun Han3, Guohao Wu3, Jing Fang4, Ying Feng4.   

Abstract

Bcl-2-associated transcription factor 1 (BCLAF1) is known to be involved in multiple biological processes. Although several splice variants of BCLAF1 have been identified, little is known about how BCLAF1 splicing is regulated or the contribution of alternative splicing to its developmental functions. Here we find that inclusion of alternative exon5a was significantly increased in colorectal cancer (CRC) samples. Knockdown of the BCLAF1 protein isoform resulting from exon5a inclusion inhibited growth and that its overexpression increased tumorigenic potential. We also found that the splicing factor SRSF10 stimulates inclusion of exon5a and has growth-inducing activity. Importantly, the upregulation of SRSF10 expression observed in clinical CRC samples parallels the increased inclusion of BCLAF1 exon5a, both of which are associated with higher tumour grade. These findings identify SRSF10 as a key regulator of BCLAF1 pre-mRNA splicing and the maintenance of oncogenic features in human colon cancer cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25091051     DOI: 10.1038/ncomms5581

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  59 in total

1.  Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.

Authors:  Xinyao Li; Zhengchang He; Bingqing Cheng; Qin Fang; Dan Ma; Tingting Lu; Danna Wei; Xingyi Kuang; Sishi Tang; Jie Xiong; Jishi Wang
Journal:  Cancer Biol Ther       Date:  2018-07-03       Impact factor: 4.742

Review 2.  Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.

Authors:  Nidhi Jyotsana; Michael Heuser
Journal:  Expert Opin Ther Targets       Date:  2017-12-20       Impact factor: 6.902

Review 3.  Competing endogenous RNA interplay in cancer: mechanism, methodology, and perspectives.

Authors:  Dong-Liang Cheng; Yuan-Yuan Xiang; Li-juan Ji; Xiao-Jie Lu
Journal:  Tumour Biol       Date:  2015-01-22

4.  MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression.

Authors:  L Liu; C Luo; Y Luo; L Chen; Y Liu; Y Wang; J Han; Y Zhang; N Wei; Z Xie; W Wu; G Wu; Y Feng
Journal:  Oncogene       Date:  2017-09-04       Impact factor: 9.867

5.  Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B.

Authors:  Xuexia Zhou; Run Wang; Xuebing Li; Lin Yu; Dan Hua; Cuiyun Sun; Cuijuan Shi; Wenjun Luo; Chun Rao; Zhendong Jiang; Ying Feng; Qian Wang; Shizhu Yu
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

6.  Bclaf1 is an important NF-κB signaling transducer and C/EBPβ regulator in DNA damage-induced senescence.

Authors:  A-w Shao; H Sun; Y Geng; Q Peng; P Wang; J Chen; T Xiong; R Cao; J Tang
Journal:  Cell Death Differ       Date:  2016-01-22       Impact factor: 15.828

7.  Liver-Specific Deletion of SRSF2 Caused Acute Liver Failure and Early Death in Mice.

Authors:  Yuanming Cheng; Chunling Luo; Wenwu Wu; Zhiqin Xie; Xiangdong Fu; Ying Feng
Journal:  Mol Cell Biol       Date:  2016-05-16       Impact factor: 4.272

8.  Bclaf1 is a direct target of HIF-1 and critically regulates the stability of HIF-1α under hypoxia.

Authors:  Anwen Shao; Yue Lang; Mengdong Wang; Chao Qin; Yu Kuang; Yide Mei; Degui Lin; Shuo Zhang; Jun Tang
Journal:  Oncogene       Date:  2020-02-06       Impact factor: 9.867

9.  Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1.

Authors:  Jun-Xian Du; Yi-Hong Luo; Si-Jia Zhang; Biao Wang; Cong Chen; Gui-Qi Zhu; Ping Zhu; Cheng-Zhe Cai; Jing-Lei Wan; Jia-Liang Cai; Shi-Ping Chen; Zhi Dai; Wei Zhu
Journal:  J Exp Clin Cancer Res       Date:  2021-05-15

Review 10.  RNA splicing factors as oncoproteins and tumour suppressors.

Authors:  Heidi Dvinge; Eunhee Kim; Omar Abdel-Wahab; Robert K Bradley
Journal:  Nat Rev Cancer       Date:  2016-06-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.